Predictors of exacerbations in chronic obstructive pulmonary disease - results from the Bergen COPD Cohort Study by Husebø, Gunnar Reksten et al.
Predictors of Exacerbations in Chronic Obstructive
Pulmonary Disease - Results from the Bergen COPD
Cohort Study
Gunnar R. Husebø1*, Per S. Bakke2, Marianne Aanerud1, Jon A. Hardie2, Thor Ueland3,4, Rune Grønseth1,
Louise J. P. Persson1, Pa˚l Aukrust3,4, Tomas M. Eagan1,2
1Dept. of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway, 2Dept. of Clinical Science, University of Bergen, Bergen, Norway, 3 Research Institute of
Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, 4 K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway
Abstract
Background: COPD exacerbations accelerate disease progression.
Aims: To examine if COPD characteristics and systemic inflammatory markers predict the risk for acute COPD exacerbation
(AECOPD) frequency and duration.
Methods: 403 COPD patients, GOLD stage II-IV, aged 44–76 years were included in the Bergen COPD Cohort Study in 2006/
07, and followed for 3 years. Examined baseline predictors were sex, age, body composition, smoking, AECOPD the last year,
GOLD stage, Charlson comorbidity score (CCS), hypoxemia (PaO2,8 kPa), cough, use of inhaled steroids, and the
inflammatory markers leucocytes, C-reactive protein (CRP), neutrophil gelatinase associated lipocalin (NGAL), soluble tumor
necrosis factor receptor 1 (sTNF-R1), and osteoprotegrin (OPG). Negative binomial models with random effects were fitted
to estimate the annual incidence rate ratios (IRR). For analysis of AECOPD duration, a generalized estimation equation
logistic regression model was fitted, also adjusting for season, time since inclusion and AECOPD severity.
Results: After multivariate adjustment, significant predictors of AECOPD were: female sex [IRR 1.45 (1.14–1.84)], age per 10
year increase [1.23 (1.03–1.47)], .1 AECOPD last year before baseline [1.65 (1.24–2.21)], GOLD III [1.36 (1.07–1.74)], GOLD IV
[2.90 (1.98–4.25)], chronic cough [1.64 (1.30–2.06)] and use of inhaled steroids [1.57 (1.21–2.05)]. For AECOPD duration more
than three weeks, significant predictors after adjustment were: hypoxemia [0.60 (0.39–0.92)], years since inclusion [1.19
(1.03–1.37)], AECOPD severity; moderate [OR 1.58 (1.14–2.18)] and severe [2.34 (1.58–3.49)], season; winter [1.51 (1.08–2.12)],
spring [1.45 (1.02–2.05)] and sTNF-R1 per SD increase [1.16 (1.00–1.35)].
Conclusion: Several COPD characteristics were independent predictors of both AECOPD frequency and duration.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common
illness worldwide, and its prevalence is increasing. The disease is
heterogeneous where some patients are more prone to have
exacerbations than other, proposed to be representing a pheno-
type of its own [1]. COPD exacerbations are associated with
accelerated worsening of lung function [2,3], increased disease
burden and mortality [4,5], thus making it important to identify
and treat these patients.
So far, the best predictors found for future exacerbations are a
history of previous exacerbations and decline in forced expiratory
volume in one second (FEV1)[6–8], together with direct or
indirect indicators of pulmonary hypertension [9,10]. Inflamma-
tory biomarkers may also be of value, alone or several combined
[11–15]. Other described predictors are depression [16], gastro-
esophageal reflux disease (GERD) [17], and quality of life [18].
However, the existing knowledge of markers that could predict
exacerbation of COPD is still limited. The inflammatory markers
associated with COPD exacerbations found so far are unspecific,
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where abnormal values can be seen in a range of conditions, thus a
continued evaluation of novel markers is warranted. Second,
although several studies have linked exacerbations with increased
inflammation [19,20], it is not fully understood whether this is a
cause or a consequence, and for this purpose longitudinal studies
are needed. Third, another measure of disease burden apart from
exacerbation frequency is their duration, for which some
associations have been described [21–24], but patients with
delayed exacerbation recovery remains difficult to identify.
This study aimed to find predictors for COPD exacerbations
and exacerbation duration, using longitudinal data from a large
Table 1. Characteristics of COPD patients according to exacerbation frequency during follow-up.
Less than 1 exacerbations
per year, n = 231
1 or more exacerbations
per year, n = 172 p-Value*
Sex, % 0.45
Women 38.1 41.9
Men 61.9 58.1
Age, Mean (SD) 62.6 (6.8) 64.3 (6.8) 0.01
Body Composition, % 0.05
Normal 61.0 48.8
Cachectic 25.1 31.4
Obese 13.9 19.8
Smoking, % 0.08
Ex 52.8 61.6
Current 47.2 38.4
Exacerbations last year prior to inclusion, % ,0.001
0–1 93.5 70.4
2+ 6.5 29.7
GOLD 2007 classification, % ,0.001
FEV1 50–80% 58.9 33.7
FEV1 30–50% 37.2 47.7
FEV1,30% 3.9 18.6
Hypoxemia, % 0.07
PaO2.8 kPa 90.9 84.7
PaO2,8 kPa 9.1 15.3
Charlson comorbidity Score, % 0.46
1 60.2 54.1
2 23.8 23.8
3 10.0 14.0
4+ 06.jan 8.1
Chronic cough, % 0.002
No 61.5 45.6
Yes 38.5 54.4
Cough with phlegm, % 0.02
No 45.9 34.3
Yes 54.1 65.7
Use of inhaled steroids, % ,0.001
No 39.4 22.1
Yes 60.6 77.9
Inflammatory markers, Median (IQR)
Leucocyte count (WBC), x109/l 7.7 (6.3 29.1) 7.9 (6.6 29.6) 0.11
C-reactive protein (CRP), ng/ml 3.4 (1.7 26.8) 4.9 (2.1 212.6) 0.003
Neutrophil gelatinase lipocalin (NGAL), 10 mg/ml 6.7 (5.1 29.5) 6.7 (5.2 29.2) 0.77
Soluble TNF receptor-1 (sTNF-R1), 100 mg/ml 6.8 (5.8 28.1) 7.1 (5.6 28.5) 0.43
Osteoprotegrin (OPG), ng/ml 5.5 (3.8 27.1) 5.9 (4.5 27.3) 0.10
*x-square for categorical variables, t-test for means and Kruskal Wallis test for medians
doi:10.1371/journal.pone.0109721.t001
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cohort study in Western Norway, examining both clinical
characteristics and novel systemic inflammatory markers.
Materials and Methods
Study population
433 Patients with COPD were included in the Bergen COPD
Cohort Study (BCCS) between February 2006 and February 2008.
All subjects in the study received written and oral information
prior to inclusion and signed informed consent. The study was
approved by the Regional Committee for Medical and Health
Research Ethics, region West (REC-West), case number 165.08.
The patients were aged between 44–76 years at the time of
inclusion. All patients had a clinical diagnosis of COPD, and a
ratio of forced expiratory volume in one second (FEV1) to forced
vital capacity (FVC) ,0.7 at least 15 minutes after bronchodila-
tion, FEV1,80% predicted by Norwegian reference values [25],
and a smoking history of more than 10 packyears. Exclusion
criteria were lung diseases other than COPD, additional active
inflammatory disease such as various autoimmune disorders, and
having a COPD-exacerbation within 4 weeks prior to inclusion.
No patients were using long-term prophylactic macrolides or other
antibiotics except one patient who was using a tetracycline for a
skin disease. The details of study design, patient selection and data
collection have been described previously [26].
Data collection
Briefly, all patients were examined by a study physician. A
physical examination, blood gas sampling, and a clinical interview
that included exacerbation history, comorbidities and medication
history were undertaken. All patients performed spirometry,
before and after bronchodilation with 0.4 mg salbutamol, using
a Viasys Masterscope. The patients were categorized into Global
Initiative for Chronic Obstructive Lung Disease (GOLD 2007)
categories II-IV based on post-bronchodilation FEV1.
Body composition was determined with bioelectrical impedance
measurements. Cachexia was defined as a fat free mass index
(FFMI) less than 17 kg/m2 in men or less than 14 kg/m2 in
women, which corresponds to the lower 95% confidence limit in a
normal population [27]. Obesity was defined as a fat mass index
(FMI) of more than 9.3 kg/m2 in men or more than 13.5 kg/m2 in
women [27].
All patients were examined and interviewed by a study
physician at the out-patient clinic every 6 months for 3 consecutive
years. At each visit, the study physician performed a detailed
clinical interview, where all exacerbations were registered.
The exacerbation count was the main outcome in this study and
was prospectively registered by the patients. We defined an
exacerbation as a worsening of respiratory symptoms for two
consecutive days or more. Exacerbations that did not require any
change in treatment were defined as mild, those requiring
treatment with antibiotics or systemic steroids by the decision of
a physician were considered moderate, and those in need for
hospital admission were considered severe [28]. Exacerbation
duration was patient reported, based entirely on symptomatic
recovery. The cut off for late recovery was set at three weeks; there
exists no definition on a long lasting exacerbation, our limit for
when to normally expect recovery was based on clinical
experience.
Laboratory measurements
Peripheral blood sampling and analyses of total leukocyte
(WBC) count, C-reactive protein (CRP), neutrophil gelatinase
associated lipocalin (NGAL), soluble tumor necrosis factor
receptor-1 (sTNF-R1), and osteoprotegrin (OPG) were performed
as previously described [26,29]. WBC and CRP were chosen as
inflammatory markers due to their availability as established
indicators of inflammation. NGAL [29], sTNF-R1 [26], and OPG
[26] have all been shown in cross-sectional analyses from our
cohort to be associated with important COPD disease character-
istics including FEV1 and exacerbation frequency.
Arterial blood gas analysis was sampled and examined within 5
minutes with a Radiometer ABL520 analyzer [30]. Hypoxemia
was defined as a partial oxygen pressure ,8.0 kPa.
Missing Values
30 patients only participated in the baseline visit. Of the 30
patients, 9 were excluded due to use of oral steroids, 8 died before
any follow-up visits were performed, in 2 patients CT scans
revealed lung cancer, and finally 11 patients withdrew their
consent to participate. Thus, 403 patients were included in the
statistical analyses. Information regarding chronic cough and
cough with phlegm was missing in 8 and 2 patients, respectively.
Plasma-sampling failed in 12 patients, and for 1, 2, and 7 patients
we lacked sufficient plasma to measure sTNF-R1, OPG, and
NGAL, respectively. Arterial blood gas analysis failed in 37 cases,
most commonly a sampling error where the patient did not want
puncture.
Statistical analyses
The exacerbation count distribution was heavily skewed to the
right. For the baseline characteristics analysis the exacerbation
count was dichotomized into patients with an average exacerba-
tion count of less than 1 per year, and those with 1 or more per
year. Mild exacerbations were not included in the exacerbation
count analysis, as in concordance with prior studies [6–8], and due
to suspected under-reporting [31]. Bivariate associations were
examined with t-tests or non-parametric tests for continuous
variables, and x-square tests for categorical variables.
Random effects negative binomial regression models condition-
al on gamma errors were fitted to estimate the incidence rate ratios
(IRR) for each potential predictor variable. Correspondingly, a
multivariate model was fitted including all the predictor variables
from the bivariate analyses except for cough with phlegm, which
showed a strong colinearity with chronic cough. The inflammatory
markers also showed strong colinearity with each other, and were
therefore tested separately added to the main model. To test for
possible interactions by sex, all variables that differed statistically
by sex at baseline were tested one at a time with an interaction
term in the final multivariate model.
In addition, exacerbations were analyzed according to duration,
searching for factors associated with recovery time exceeding three
weeks. A generalized estimating equation logistic regression model
with exchangeable correlation structure was fitted, testing poten-
tial predictor variables both separate and multivariate. Stata 12.1
(StataCorp LP, College Station, TX, USA) was used for the
statistical analyses.
Results
350 out of the 403 COPD patients experienced one or more
exacerbations during the three years of follow-up. A total of 1696
exacerbations were registered, of which 393 were classified as
mild, 933 as moderate, and 370 as severe. Women had more
exacerbations than men, the difference consisting of more
exacerbations of moderate severity (p = 0.001). The median
duration for an exacerbation was 14 days (interquartile range
15 days) .
Predictors of COPD Exacerbations
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The baseline characteristics of the study population are
presented in Table 1. Patients with a higher exacerbation rate
were slightly older, more cachectic or obese, had a higher number
of exacerbations before inclusion, had a lower FEV1 in %
predicted, and had higher frequencies of chronic cough and cough
with phlegm. They were also more frequent users of inhaled
corticosteroids (ICS). Of the measured inflammatory markers
upon inclusion, only CRP was significantly higher in patients with
more frequent exacerbations during follow-up.
Table 2. Bivariate predictors of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a
random effects negative binomial model.
Baseline explanatory variables IRR (95% CI) p-Value
Sex
Men 1
Women 1.27 (0.99 21.63) 0.06
Age
per 10 years increase 1.24 (1.04 21.48) 0.02
Body Composition
Normal 1
Cachectic 1.41 (1.07 21.85) 0.02
Obese 1.23 (0.88 21.71) 0.23
Smoking
Ex 1
Current 0.83 (0.65 21.06) 0.13
Exacerbations 12 months before inclusion
0–1 1
2+ 2.74 (2.08 23.61) ,0.001
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.75 (1.38 22.23) ,0.001
FEV1,30% 3.59 (2.51 25.13) ,0.001
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 1.61 (1.11 22.34) 0.01
Charlson comorbidity Score
1 1
2 1.07 (0.79 21.43) 0.67
3 1.21 (0.82 21.77) 0.33
4+ 1.37 (0.86 22.21) 0.19
Chronic cough
No 1
Yes 1.73 (1.36 22.19) ,0.001
Cough with phlegm
No 1
Yes 1.38 (1.08 21.77) 0.01
Use of inhaled steroids
No 1
Yes 2.11 (1.62 22.74) ,0.001
Inflammatory markers *
Leucocyte count (WBC) 1.13 (1.00 21.29) 0.05
C-reactive protein (CRP) 1.13 (1.01 21.26) 0.04
Neutrophil gelatinase lipocalin (NGAL) 1.01 (0.90 21.13) 0.89
Soluble TNF receptor-1 (sTNF-R1) 1.05 (0.94 21.18) 0.36
Osteoprotegrin (OPG) 1.13 (1.01 21.27) 0.04
*Per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t002
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Factors associated with annual exacerbation rate
Table 2 shows bivariate associations between possible predictor
variables and annual exacerbation rate. Age, cachexia, number of
exacerbations the year before inclusion, GOLD stage, hypoxemia,
cough symptoms, and use of ICS were all associated with a higher
IRR. Higher levels of CRP and OPG at baseline, but not levels of
WBC, NGAL and sTNF-R1, were predictive of a higher
exacerbation rate within the follow-up.
The adjusted IRRs are shown in Table 3. Significant predictors
of a higher risk for moderate or severe exacerbations were female
sex, higher age, a history of frequent exacerbations prior to
inclusion, higher GOLD stage, chronic cough and use of ICS. Of
all potential interactions between sex and the other variables
tested, none were found to be statistically significant.
Thus, mostly the associations seen in the bivariate analyses were
confirmed, except for the inflammatory markers, which were not
Table 3. Multivariate model of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a
random effects negative binomial model.
Baseline explanatory variables IRR 95% CI p-Value
Sex
Men 1
Women 1.45 (1.14 21.84) 0.002
Age
per 10 years increase 1.23 (1.03 21.47) 0.02
Body composition
Normal 1
Cachectic 1.19 (0.91 21.56) 0.22
Obese 1.23 (0.90 21.69) 0.19
Smoking
Ex 1
Current 0.93 (0.73–1.19) 0.56
Exacerbations last year
0–1 1
2+ 1.65 (1.24–2.21) 0.001
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.36 (1.07–1.74) 0.01
FEV1,30% 2.90 (1.98–4.25) ,0.001
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 1.10 (0.79–1.54) 0.58
Charlson comorbidity Score
1 1
2 0.97 (0.74–1.27) 0.81
3 0.98 (0.68–1.42) 0.93
4+ 0.98 (0.61–1.57) 0.93
Chronic cough
No 1
Yes 1.64 (1.30–2.06) ,0.001
Use of inhaled steroids
No 1
Yes 1.57 (1.21–2.05) 0.001
Inflammatory markers added one each, to the above model *
Leucocyte count (WBC) 1.04 (0.93–1.17) 0.49
C-reactive protein (CRP) 1.03 (0.93–1.14) 0.56
Neutrophil gelatinase lipocalin (NGAL) 0.99 (0.89–1.10) 0.85
Soluble TNF receptor-1 (sTNF-R1) 1.03 (0.92–1.16 0.56
Osteoprotegrin (OPG) 0.92 (0.82–1.03) 0.15
*IRR per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t003
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Table 4. Bivariate predictors of copd-exacerbation duration more than three weeks, estimated by a generalized estimation
equation logistic regression model.
Baseline explanatory variables OR 95% CI p-Value
Sex
Men 1
Women 1.02 (0.79 21.31) 0.90
Age
per 10 years increase 0.94 (0.78 21.13) 0.52
Body Composition
Normal 1
Cachectic 1.07 (0.81 21.43) 0.63
Obese 1.43 (1.02 22.00) 0.04
Smoking
Ex 1
Current 1.24 (0.96 21.59) 0.10
Exacerbations 12 months before inclusion
0–1 1
2+ 1.20 (0.91 21.59) 0.20
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.11 (0.84 21.45) 0.47
FEV1,30% 1.05 (0.72 21.53) 0.79
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 0.83 (0.57 21.22) 0.34
Charlson comorbidity Score
1 1
2 1.51 (1.13 22.02) 0.005
3 1.26 (0.85 21.85) 0.25
4+ 1.21 (0.77 21.89) 0.42
Chronic cough
No 1
Yes 1.43 (1.11 21.85) 0.005
Cough with phlegm
No 1
Yes 1.18 (0.91 21.53) 0.22
Use of inhaled steroids
No 1
Yes 0.97 (0.72 21.30) 0.83
Time since inclusion
Per year increase 1.2 (1.05–1.36) 0.006
Exacerbation severity
Mild 1
Moderate (use of antibiotics or steroids) 1.51 (1.12 22.01) 0.006
Severe (admission to hospital) 2.25 (1.60 23.17) ,0.001
Season
Summer 1
Autumn 1.24 (0.90 21.71) 0.18
Winter 1.48 (1.09 22.01) 0.01
Spring 1.36 (0.99 21.86) 0.06
Inflammatory markers *
Leucocyte count (WBC) 1.11 (0.98 21.25) 0.10
Predictors of COPD Exacerbations
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significant predictors of later exacerbations in the model where a
large number of covariables were included.
Factors associated with exacerbation duration more than
three weeks
Table 4 and 5 show bi- and multivariate associations between
potential predictor variables and exacerbations lasting more than 3
weeks. Variables with significant bivariate associations were
obesity, Charlson comorbidity score (CCS) 2, chronic cough,
increasing time since inclusion, increasing exacerbation severity,
exacerbations during winter and spring (December-February and
March-May), and higher levels of baseline sTNF-R1. The same
variables remained significant after multivariate adjustment, with
the exception of obesity, CCS and chronic cough. The presence of
hypoxemia was after adjustment associated with exacerbation
duration shorter than three weeks. Age, sex, GOLD-stage,
smoking status and use of medication along with the other
inflammatory markers did not show a significant association with
exacerbation duration.
Discussion
We used prospective follow-up data from a large cohort study
from western Norway to identify predictors for COPD exacerba-
tion frequency and duration. The best predictors of future
exacerbations in this study were a history of frequent exacerba-
tions prior to inclusion, lower lung function, increasing age, and
female sex, confirming the findings of earlier studies [6–8].
Furthermore, we identified some easily accessible clinical variables
independently associated with increased exacerbation rates such as
chronic cough and the use of inhaled steroids.
Exacerbation duration was significantly associated with exacer-
bation severity and season, which is in accordance with other
studies [21,22,24]. In addition, we identified an association
between exacerbation duration and both hypoxemia and sTNF-
R1 not demonstrated before.
The main strengths of this study were the prospective design,
the large number of patients, and the assessment of a series of
different variables. This allowed for the use of complex regression
analysis and adjustment for several key variables. Attendance rate
at the visits was high, varying between 86 and 97 percent. The
longitudinal design allowed for predictive statistical modeling,
however, no intervention was done, and the concept prediction
should not be confused with causality.
The statistical analysis of exacerbation frequency is complex,
due to its distorted distribution and due to clustering both in
subject and time [32]. One approach is to compare the frequent
vs. the non-frequent exacerbator using logistic regression. How-
ever, negative binomial or Poisson regression may be more suited
[33]. In our study we treated the exacerbation frequency as a
count variable. Both Poisson and negative binomial models were
considered, but due to overdispersion of the data the latter model
was preferred, though a Poisson model was also fitted producing
almost identical results (not shown here).
The exacerbation data was acquired through interview by the
study physician, with the aid of the patients’ journal present. The
majority of patients (n = 350) lived in a proximity to our hospital,
which would have led them to attend our hospital in an
emergency. Due to the long follow-up, we did not use an
exacerbation diary or other grading tools although these methods
have been validated [34]. Thus, we believe under-reporting of
severe exacerbations were highly unlikely and under-reporting of
moderate exacerbations unlikely but probably present to some
extent. Regarding severe exacerbations, apart from hospital
admission and duration, we had no other clinical information to
validate its severity, and due to this we chose to analyze severe and
moderate exacerbations together. For the analysis of exacerbation
duration, mild exacerbations were included in the model despite
the limitations in in the data collection mentioned above, and this
should be taken into consideration when interpreting the data.
This study showed a large diversity in both exacerbation
frequency and duration. In agreement with earlier studies, a
person with exacerbations in the past is more likely to experience
exacerbations in the future [6–8]. Earlier studies have shown that
women experience more symptoms from their illness, but
mortality rates have shown gender equality [35]. A similar picture
emerged in our study, where women experienced a higher rate of
moderate exacerbations, but not severe exacerbations requiring
hospital admission. Whether this represents a genuine increase in
exacerbations or an increased tendency among women to seek
medical attention remains unclear.
Somewhat surprising, but also seen before [6], was the finding
that ex-smokers had no reduction of the exacerbation count
compared to active smokers. This could imply that smoking
cessation was too late, and that disease progression continued after
smoking cessation. Another explanation may be that most of our
cohort consisted of a selection of COPD patients having had prior
consultations with pulmonary physicians [26], which might affect
smoking habits, where perhaps the most symptomatic patients
were more likely to have quit prior to entering the study. Different
exacerbation rates between smokers and ex-smokers have been
seen in COPD patients selected from a more general population
[36]. Finally, time since smoking cessation was not a significant
variable in our study (data not shown), but our study may not have
been powered to examine that properly.
The association between exacerbation frequency and use of ICS
may seem paradoxical as large randomized studies have shown a
modest, but significant decrease in exacerbation risk with their use
[37–40]. Nevertheless, randomized trials often include highly
selected study populations, and non-intervention cohort studies as
ours add to the existing knowledge. Several studies have shown an
association between ICS and pneumonia rate [41–43], and it is
Table 4. Cont.
Baseline explanatory variables OR 95% CI p-Value
C-reactive protein (CRP) 0.94 (0.83 21.07) 0.36
Neutrophil gelatinase lipocalin (NGAL) 1.06 (0.93 21.21) 0.37
Soluble TNF receptor-1 (sTNF-R1) 1.14 (1.01 21.28) 0.04
Osteoprotegrin (OPG) 0.97 (0.85 21.09) 0.59
*IRR per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t004
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possible that use of ICS comes with an increased risk for infectious
exacerbations of COPD. We observed an exacerbation IRR of
1.57 in ICS-users after multivariate adjustments, but still we
cannot exclude a selection bias since these patients may have
received their ICS due to worsening of symptoms not accounted
for in our model. Also, in our study, a majority of the patients
using ICS (91%) were using them in combination with a long
acting beta-2-agonist (LABA), making it difficult to separate the
effect of the ICS vs. the LABA. Thus, our observation of increased
exacerbation rate in ICS-users cannot be interpreted as a causal
effect, but nonetheless, an observation of ICS-use may aid in
identifying a patient with increased risk for future exacerbations.
A primary objective in this study was to evaluate the association
between systemic inflammation and exacerbation rate measuring
inflammatory markers at inclusion. In our study we only measured
the inflammatory markers at baseline, and their predictive value
Table 5. Multivariate model of copd-exacerbation duration more than three weeks, estimated by a generalized estimation
equation logistic regression model.
Baseline explanatory variables OR 95% CI p-Value
Sex
Men 1
Women 1.17 (0.88–1.56) 0.29
Age
per 10 years increase 0.88 (0.70–1.10) 0.27
Body Composition
Normal 1
Cachectic 0.92 (0.66–1.29) 0.63
Obese 1.35 (0.93–1.98) 0.11
Smoking
Ex 1
Current 1.29 (0.95–1.76) 0.11
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.23 (0.90–1.67) 0.19
FEV1,30% 1.18 (0.75–1.87) 0.48
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 0.60 (0.39–0.92) 0.02
Charlson comorbidity Score
1 1
2 1.14 (0.81–1.59) 0.46
3 1.15 (0.72–1.82) 0.56
4+ 1.36 (0.76–2.42) 0.30
Chronic cough
No 1
Yes 1.29 (0.97–1.71) 0.08
Time since inclusion
Per year increase 1.19 (1.03–1.37) 0.02
Exacerbation severity
Mild 1
Moderate (use of antibiotics or steroids) 1.58 (1.14–2.18 0.006
Severe (admission to hospital) 2.34 (1.58–3.49) ,0.001
Season
Summer 1
Autumn 1.33 (0.94–1.89) 0.11
Winter 1.51 (1.08–2.12) 0.02
Spring 1.45 (1.02–1.35) 0.04
Soluble TNF receptor-1 (sTNF-R1)
per 1 SD increase of marker value 1.16 (1.00–1.35) 0.05
doi:10.1371/journal.pone.0109721.t005
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for an event up to three years later is likely to decrease as time goes
by. CRP and OPG at baseline were bivariately associated with the
exacerbation rate, but not after multivariate adjustment. WBC,
fibrinogen and uric acid have independently shown predictive
value in other studies [6,11,14], indicating that systemic inflam-
mation may be a prerequisite for exacerbations. CRP has shown
predictive value in combination with the WBC and fibrinogen
[12], and the specificity and sensitivity may be further improved
with the construction of so called inflammomas [15], containing
three or more easily accessible markers, or with sputum samples,
nonetheless these approaches have still yielded limited clinical
value, so the search for additional markers should continue.
It is challenging to predict those patients in risk for a long lasting
exacerbation. Dissimilar from the exacerbation rate, factors like
prior exacerbations and FEV1 did not seem to affect the duration.
Increasing values of sTNF-R1 as a marker of activity in the TNF
system was associated with late exacerbation recovery, and may be
a marker of chronic inflammation in COPD. On the other hand,
sTNF-R1 is associated with important comorbidities difficult to
adjust for [26], and this finding must be confirmed in other studies.
The association between duration and season can be linked to
both lower temperature [44] and seasonality of viral infections
[45], and was anticipated; on the other hand, the observation of
reduced recovery time in patients with hypoxemia was unexpect-
ed. Hypoxemic patients are likely to have more symptoms in their
stable state, perhaps making it difficult to distinguish between the
exacerbated and the stable state, which might affect their
exacerbation reporting. Nonetheless, this observation should be
confirmed in other studies.
This study illustrates the vicious circle affecting a large
proportion of COPD patients, where one exacerbation predisposes
for the next, leading to an ever increasing disease burden. This
underscore the need for markers that could further identify
patients at risk, as well as the need for proper intervention in these
patients. We identify several clinical parameters for recognition of
patients at risk for frequent or long lasting exacerbations, making it
possible for earlier or more extensive preventive intervention.
Finally, there is still a lack of useful inflammatory markers, both to
identify patients with high risk of future exacerbations, as well as a
diagnostic tool to detect ongoing exacerbations.
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